Autonomous Systems Spółka z Ograniczoną Odpowiedzialnością (KRS 0000735553, NIP 6312679996) is a Polish company, headquartered in Gliwice, Śląskie voivodeship. AUTONOMOUS SYSTEMS operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since June 8, 2018. AUTONOMOUS SYSTEMS's most recently reported net revenue was 3.4 M PLN for 2024.
Negative equity
Negative equity in 1 of 6 available reporting years.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Autonomous Systems
Identity
- Name
- Autonomous Systems Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- June 8, 2018
- Registry status as of
- June 14, 2026
- Latest entry
- June 14, 2026
- Founding act
- 04.06.2018 R.
Articles of association history (10)
- June 4, 2018: 04.06.2018 R.
- December 21, 2018: 21.12.2018 R. - REP.A NR 5641/2018, NOTARIUSZ ZUZANNA WOJTASZEK-BAŁAZIŃSKA, KANCELARIA NOTARIALNA W KATOWICACH - ZMIANA: §5; §6
- October 16, 2019: 16.10.2019 R. - REP.A NR 6263/2019, NOTARIUSZ PIOTR MARQUARDT, KANCELARIA NOTARIALNA W KATOWICACH - ZMIANA §5
- January 16, 2020: 16.01.2020 R. - REP.A. NR 200/2020, NOTARIUSZ SYLWIA JONEK, KANCELARIA NOTARIALNA W BYTOMIU ZMIENIONO: §5
- December 1, 2021: 01.12.2021 R. - REP. A. NR 5186/2021, NOTARIUSZ SYLWIA JONEK, KANCELARIA NOTARIALNA W BYTOMIU - ZMIENIONO: §5 UMOWY SPÓŁKI
- December 29, 2021: 29.12.2021 R. - REP. A NR 5594/2021, NOTARIUSZ SYLWIA JONEK, KANCELARIA NOTARIALNA W BYTOMIU; ZMIENIONO: § 5
- November 9, 2022: 09.11.2022 R. - REP.A NR 4787/2022, NOTARIUSZ SYLWIA JONEK, KANCELARIA NOTARIALNA W BYTOMIU - ZMIENIONO: §5, §6, §9, §10; DODANO: §10'
- December 13, 2023: 13.12.2023 R. - REP.A NR 6860/2023, NOTARIUSZ SYLWIA JONEK, KANCELARIA NOTARIALNA W BYTOMIU - ZMIENIONO: §5, §6, §9 UST.1, §10 UST.3 ORAZ 21.12.2023 R. - REP.A NR 7081/2023, NOTARIUSZ SYLWIA JONEK, KANCELARIA NOTARIALNA W BYTOMIU - ZMIENIONO: §5, §6 PKT 1)
- October 29, 2024: 29.10.2024 R. - REP.A NR 6349/2024, NOTARIUSZ SYLWIA JONEK, KANCELARIA NOTARIALNA W BYTOMIU - ZMIENIONO: §5, §6, §9 UST.1, §10 UST.3 ; 19.12.2024 R. - REP.A NR 7409/2024, NOTARIUSZ SYLWIA JONEK, KANCELARIA NOTARIALNA W BYTOMIU - ZMIENIONO: §5, §6 PKT 1)
- April 30, 2025: 30.04.2025 R. - REP.A NR 2572/2025, NOTARIUSZ SYLWIA JONEK, KANCELARIA NOTARIALNA W BYTOMIU - ZMIENIONO: §5, §6 PKT 1)
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Address and contact
- Address
- UL. BOJKOWSKA, 37J, 44-100, GLIWICE, POLSKA
- Voivodeship
- ŚLĄSKIE
- District
- GLIWICE
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-34901-82315-VHJGA-28
Risk and payment profile - Autonomous Systems
Credibility rating
45.8 / 100
Average credibility
Insolvency risk
Low
Elevated threat
Closure risk
27
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
Spółka wykazuje sygnały niestabilności organizacyjnej: częste zmiany właścicieli. Może to wskazywać na podwyższone ryzyko współpracy.
Shareholder changes
8
8/8 yrs
Board changes
1
1/8 yrs
PKD changes
0
0/8 yrs
Name changes
0
0/8 yrs
Data from 8 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: D (46/100)
Trend: stable (+1.6 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2018–2024
Current: 453.3 K PLN
Safe: 136.0 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Autonomous Systems
Founded
June 8, 2018
8 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
GLIWICE
ŚLĄSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
307.8 K PLN
5,904 shares total
Shareholders
1
shareholder
Board
2 people
Filed years
6 years
2018–2024 · profitable: 0/6
Registry entries
38
latest: June 14, 2026
Risk signals
Revenue
3.4 M PLN
2024
Net profit
-3.2 M PLN
2024
Assets
7.4 M PLN
2024
Equity
6.5 M PLN
2024
EBITDA
-1.6 M PLN
2024
Valuation
2.9 M PLN
Low confidence
Low confidence
Companies in the same location
EU Funds
Projects co-financed by the European Union for Autonomous Systems - total value, EU contribution and the company's largest awards.
Projects
2
EU co-financing
5.4 M PLN
Total project value
9.8 M PLN
Eligible spending
9.4 M PLN
Funds
Operational programmes
- Program Operacyjny Inteligentny Rozwój
- Regionalny Program Operacyjny Województwa Śląskiego na lata 2014-2020
Largest projects
Top 2 by EU co-financing
| Project | Fund | EU co-financing | Value | Rate | Period |
|---|---|---|---|---|---|
Public procurement
Trademarks
Reviews
Rate business credibility - Autonomous Systems.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
